Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKZF2 | Q9UKS7 | 6/20 | 0.69 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.69 |
| ▸ | CRBN | Q96SW2 | 14/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25010615 | 0.92 | IKZF2 (0.69) | IKZF2IKZF1CRBN | |
| SCHEMBL23509532 | 0.91 | IKZF2 (0.68) | IKZF2IKZF1CRBN | |
| SCHEMBL24850604 | 0.90 | IKZF2 (0.73) | IKZF2IKZF1CRBN | |
| SCHEMBL25079613 | 0.90 | IKZF2 (0.65) | IKZF2IKZF1CRBN | |
| SCHEMBL27061682 | 0.89 | IKZF2 (0.69) | IKZF2IKZF1CRBN | |
| SCHEMBL31065139 | 0.88 | IKZF2 (0.65) | IKZF2IKZF1CRBN | |
| SCHEMBL23092298 | 0.88 | IKZF2 (0.65) | IKZF2IKZF1CRBN | |
| SCHEMBL26609218 | 0.88 | IKZF2 (0.66) | IKZF2IKZF1CRBN | |
| SCHEMBL26609889 | 0.88 | IKZF2 (0.59) | IKZF2IKZF1CRBN | |
| SCHEMBL23092333 | 0.88 | IKZF2 (0.65) | IKZF2IKZF1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025863-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2023066350-A1 | CRBN E3 LIGASE LIGAND COMPOUND, PROTEIN DEGRADING AGENT DEVELOPED ON THE BASIS OF LIGAND COMPOUND, AND THEIR APPLICATIONS | 标新生物医药科技(上海)有限公司 | 2023-04-27 | — | — | WO | disclosed |
| WO-2021051034-A1 | RAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025863-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SOS1, SOS2, SOST | IKZF2 2621/4885IKZF1 1510/4885CRBN 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.